drugset

drugset / Trial / NCT00875771

Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients

NCT00875771 ↗

Phase 2 Completed 80 enrolled Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) Hoffmann-La Roche · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine efficacy and safety of the biweekly scheme with Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer.

Timeline

Start: 2009-04
Primary completion: 2012-05
Completion: 2012-05

Publications

Garcia-Alfonso P, Chaves M, Munoz A, Salud A, Garcia-Gonzalez M, Gravalos C, Massuti B, Gonzalez-Flores E, Queralt B, Lopez-Ladron A, Losa F, Gomez MJ, Oltra A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer. 2015 Apr 29;15:327. doi: 10.1186/s12885-015-1293-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	5 mg/kg	Intravenous
Subject	Capecitabine	Small molecule	1000 mg/m2	Oral
Subject	Irinotecan	Small molecule	175 mg/m2	Intravenous

Indications